

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
Ying Tang	01/18/2011
<b>RECEIVING PARTY DATA</b>	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
<b>PROPERTY NUMBERS Total: 1</b>	
Property Type	Number
Application Number:	12095398
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(317)276-3861
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	patents@lilly.com
Correspondent Name:	Eli Lilly and Company
Address Line 1:	P. O. Box 6288
Address Line 2:	Patent Division
Address Line 4:	Indianapolis, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X17062
NAME OF SUBMITTER:	Linda M. Durbin
Total Attachments: 2 source=X17062Assignment#page1.tif source=X17062Assignment#page2.tif	

CH \$40.00 12095398

**ASSIGNMENT****WHEREAS,**

**Ying TANG**  
**San Diego, California**  
**Citizenship: China**

is a co-inventor (with co-inventors Barrett Allan, Chi-Kin Chow, Ling Liu, Jirong Lu and Jonathan Wendell Tetreault), of an invention that is the subject of a patent ("Patent") which is entitled Anti-IL-17 Antibodies containing 79 pages and 2 sheets of drawings, and which was filed:

- in the United States Patent and Trademark Office
- in the United Kingdom Patent Office
- in the European Patent Office
- in the Spanish Patent Office as a European Application
  
- as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office

And accorded the following serial number and application filing date: 12/095,398 filed May 29, 2008 and granted on November 23, 2010 as Patent No. 7,838,638.

**WHEREAS ELI LILLY AND COMPANY**, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Patent.

**NOW, THEREFORE**, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Patent, , including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

